Empagliflozin in Acute Myocardial Infarction in Patients with and Without Type 2 Diabetes: A Pre-Specified Analysis of the EMPACT-MI Trial
Patients with acute MI, LVEF <45% and/or congestion who had T2DM were at a higher risk of mortality than those without T2DM. Empagliflozin reduced first and total HF hospitalizations regardless of the presence or absence of T2DM.
Authors
- Josephine Harrington (ORCID: https://orcid.org/0000-0001-5169-117X)
- Mark C. Petrie (ORCID: https://orcid.org/0000-0002-6333-9496)
- Deepak L. Bhatt (ORCID: https://orcid.org/0000-0002-1278-6245)
- Mikhail Sumin (ORCID: https://orcid.org/0000-0002-3827-5793)
- Adrian F. Hernandez (ORCID: https://orcid.org/0000-0003-3387-9616)
- Antoni Bayes-genis A (ORCID: https://orcid.org/0000-0002-3044-197X)
- Martina Brueckmann (ORCID: https://orcid.org/0000-0003-1215-0746)
- Javed Butler (ORCID: https://orcid.org/0000-0001-7683-4720)
- W Schuyler Jones
- Morten Schou (ORCID: https://orcid.org/0000-0002-4271-2466)
- James Louis Januzzi (ORCID: https://orcid.org/0000-0002-8338-1798)
- Xavier Rosselló (ORCID: https://orcid.org/0000-0001-6783-8463)
- Johann Bauersachs
- Tomasz Gąsior (ORCID: https://orcid.org/0000-0001-5088-4164)
- Renato D. Lópes (ORCID: https://orcid.org/0000-0003-2999-4961)
- Vijay Chopra (ORCID: https://orcid.org/0000-0001-9512-1718)
- Shelley R. Zieroth (ORCID: https://orcid.org/0000-0002-6145-9814)
- Michaela Mattheus (ORCID: https://orcid.org/0000-0002-8611-6236)
- Stefan D. Anker (ORCID: https://orcid.org/0000-0003-3331-7314)
- Peter van der Meer (ORCID: https://orcid.org/0000-0002-9705-4413)
- M. Cecilia Bahit
- Piotr Ponikowski
- Offer Amir
- Jacob A. Udell
Institutions
- University of Copenhagen (DK)
- Boehringer Ingelheim (Germany) (DE)
- University Medical Center Groningen (NL)
- Harvard University (US)
- University of Groningen (NL)
- Duke University (US)
- University of Mannheim (DE)
- University of Toronto (CA)
- Heidelberg University (DE)
- Hadassah Medical Center (IL)
- Women's College Hospital (CA)
- Herlev Hospital (DK)
- Toronto General Hospital (CA)
- Max Super Speciality Hospital (IN)
- Gentofte Hospital (DK)
- British Heart Foundation (GB)
- Medizinische Hochschule Hannover (DE)
- University of Mississippi (US)
- Wroclaw Medical University (PL)
- Massachusetts General Hospital (US)
- Clinical Research Institute (US)
- Mount Sinai Hospital (US)
- Baylor Medical Center at Garland (US)
- Baim Institute for Clinical Research (US)
- Instituto de Neurología Cognitiva (AR)
- Health Research Institute of the Balearic Islands (ES)
- German Centre for Cardiovascular Research (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- WSB University (PL)
- Boehringer Ingelheim (China) (CN)
- Duke University Hospital (US)
- Hospital Universitari Germans Trias i Pujol (ES)
- University Medical Centre Mannheim (DE)
- Baylor Scott & White Health (US)
- University of Manitoba (CA)
- Universitat de les Illes Balears (ES)
- Charité - Universitätsmedizin Berlin (DE)
- University of Glasgow (GB)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1002/ejhf.3548
- Citations
- 7
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.50
Funders
- Eli Lilly and Company
- Boehringer Ingelheim España